Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain tumor or aneurysm first? study weighs the safer sequence

NCT ID NCT07809178

Knowledge-focused Sponsor: Cheng sen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 09, 2026 · Last updated Sep 10, 2026 · Updated 1 time

Summary

Researchers are observing patients in China who have both a tumor in the sellar region of the brain and an unruptured intracranial aneurysm. The study compares three approaches: removing the tumor before treating the aneurysm, treating the aneurysm before removing the tumor, or removing the tumor while leaving the aneurysm under observation. By tracking aneurysm growth, rupture, tumor complications, hormone levels, vision, and recurrence, the team aims to learn which condition should be treated first.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If one treatment order proves safer, doctors could adopt a standard sequence for patients who have both a sellar tumor and an unruptured aneurysm.
What could go wrong
This observational study tracks patients rather than assigning them to a treatment, so differences between groups may reflect patient characteristics rather than the order of treatment. Results may not apply outside the Chinese population studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 608 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients diagnosed of tumor in sellar region with unruptured intracranial aneurysms in the Chinese population

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Preoperative enhanced head MRI showing a suspected diagnosis of a sella region lesion, and preoperative head CTA/DSA confirming an unruptured intracranial aneurysm. 2. Patients with primary sella region tumor and unruptured intracranial aneurysms that have not previously accepted surgical treatment. 3. Patients with tumor in sellar region requiring craniotomy or endoscopic transnasal surgery and/or an aneurysm requiring craniotomy, endovascular treatment, or observation only. 4. The patients are in good general health, without severe underlying medical conditions, and capable of tolerating surgical treatment. 5. Patients or their legal guardians have signed an informed consent form and voluntarily agreed to participate in the clinical trial. Exclusion Criteria: 1. Patients with recurrent sella region tumors. 2. Patients with previously treated intracranial aneurysm. 3. Pregnant or breastfeeding women. 4. Any other condition that, in the investigator's judgment, makes the patient unsuitable for trial participation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chordoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain aneurysm central nervous system cyst chordoma craniopharyngioma germinoma hypothalamic neoplasm meningioma optic pathway glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chordoma Craniopharyngioma Germinoma Hypothalamic neoplasms Meningioma Optic pathway glioma Pituitary neuroendocrine tumor Rathke cleft cysts Unruptured intracranial aneurysms

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beijing Tiantan Hospital affiliated to Capital Medical University

    Beijing, China, 100070, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.